Physician profile
George E Burns
NPI 1508858044
$2,692.63
in general payments reported to CMS, 2019-2025
26 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $379 · 2021: $202 · 2022: $194 · 2023: $318 · 2024: $413 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $581.57 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $390.37 | 2019-2023 | Ilumya, Blu-U, Odomzo |
| Abbvie INC. | $255.52 | 2019-2024 | Humira, Skyrizi |
| Genzyme Corporation | $235.12 | 2019-2025 | |
| Lilly USA, LLC | $218.64 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $143.44 | 2020-2025 | Siliq, Targretin, Cabtreo |
| Janssen Biotech, INC. | $122.03 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $101.35 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $85.98 | 2021-2024 | Libtayo |
| Ucb, INC. | $75.48 | 2023-2025 | Bimzelx, Cimzia |
| Kyowa Kirin, INC. | $71.25 | 2020-2025 | |
| Organogenesis INC. | $54.81 | 2021-2024 | |
| Leo Pharma INC. | $38.56 | 2019 | |
| Dermavant Sciences, INC. | $35.48 | 2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.90 | 2024 | Spevigo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.95 | 2022 | |
| Fresenius Kabi USA, LLC | $25.27 | 2024 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $24.70 | 2023 | Sotyktu |
| Next Science LLC | $24.13 | 2023 | Surgx, Blastx, Xperience |
| Incyte Corporation | $23.93 | 2022 | |
| Fidia Pharma USA INC. | $22.87 | 2024 | |
| Convatec INC. | $22.70 | 2024 | |
| Biofrontera INC. | $21.87 | 2019 | |
| Celgene Corporation | $18.37 | 2019 | |
| Smith+Nephew, INC. | $17.56 | 2019 | |
| Dermira, INC. | $16.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.